Latest Leverage News

Eden Innovations has expanded its EdenCrete Pz7 installations across North America, launched a new defence-focused division EdenShield, and eliminated costly debt, positioning for growth with a $4 million capital raise.

4DMedical has made significant strides in commercial adoption of its CT:VQ™ lung imaging technology, securing top US hospital contracts, regulatory approvals in Europe and the UK, and a major pharmaceutical partnership, all backed by strong capital raises and inclusion in the S&P/ASX 200.

Alexium International Group has boosted sales to $1.03 million following its Microtek Laboratories acquisition, shifting focus to manufacturing-led growth and expanding its flame-retardant and thermal regulation product lines.

Regis Healthcare expects FY26 underlying EBITDA of approximately $135 million, buoyed by near-record occupancy and a disciplined capital strategy amid evolving government reforms.

Artrya has fully integrated its Salix platform at Tanner Health, is preparing two more US sites for launch, and is finalising FDA submission for its Coronary Flow module, backed by a strong cash position of $76.6 million.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

Microba Life Sciences reported a 99% year-on-year surge in core testing revenue for Q3 FY26, propelled by strong test volume growth and new clinic contracts in Australia and the UK. The company is advancing a major product release and negotiating a significant corporate transaction to bolster its financial position.

Rincon Resources has validated historic assays revealing a broad, high-grade gold-copper corridor at its Telfer South Project and completed a $3.1 million capital raise to advance exploration.

Yugo Metals (ASX:YUG) secured government approval for its Petrovo tenement in Bosnia, while initial drilling at Sinjakovo’s Kovacevac and Erak prospects delivered promising polymetallic results. The company also appointed Petar Tomašević as permanent CEO, positioning itself for further exploration progress.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Renowned boosts its US footprint with a landmark RE/MAX partnership and expands multi-year brokerage deals in Australia and New Zealand, driving 3% group revenue growth and positive cash flow in Q3 FY26.

Hot Chili Limited secured A$40 million in a private placement to fast-track development of its Costa Fuego copper-gold project in Chile, buoyed by significant high-grade drill results extending the La Verde discovery footprint.